159 related articles for article (PubMed ID: 15383758)
1. Acid suppression and chemoprevention in Barrett's oesophagus.
Raj A; Jankowski J
Dig Dis; 2004; 22(2):171-80. PubMed ID: 15383758
[TBL] [Abstract][Full Text] [Related]
2. Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus.
Jankowski JA; Anderson M
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():71-80; discussion 95-6. PubMed ID: 15456468
[TBL] [Abstract][Full Text] [Related]
3. The evidence base of proton pump inhibitor chemopreventative agents in Barrett's esophagus--the good, the bad, and the flawed!
Leedham S; Jankowski J
Am J Gastroenterol; 2007 Jan; 102(1):21-3. PubMed ID: 17266685
[TBL] [Abstract][Full Text] [Related]
4. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
[TBL] [Abstract][Full Text] [Related]
5. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
[TBL] [Abstract][Full Text] [Related]
6. The length of newly diagnosed Barrett's oesophagus and prior use of acid suppressive therapy.
El-Serag HB; Aguirre T; Kuebeler M; Sampliner RE
Aliment Pharmacol Ther; 2004 Jun; 19(12):1255-60. PubMed ID: 15191506
[TBL] [Abstract][Full Text] [Related]
7. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
Cooper BT; Chapman W; Neumann CS; Gearty JC
Aliment Pharmacol Ther; 2006 Mar; 23(6):727-33. PubMed ID: 16556174
[TBL] [Abstract][Full Text] [Related]
8. [Medical treatment of Barrett's esophagus].
Kinoshita Y; Yuki T
Nihon Rinsho; 2005 Aug; 63(8):1449-53. PubMed ID: 16101238
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and treatment of Barrett's oesophagus. A general survey.
Petrakis IE; Sciacca V; Iascone C
Acta Chir Belg; 2001; 101(2):53-8. PubMed ID: 11396051
[TBL] [Abstract][Full Text] [Related]
10. Should patients with Barrett's oesophagus be kept under surveillance? The case for.
Armstrong D
Best Pract Res Clin Gastroenterol; 2008; 22(4):721-39. PubMed ID: 18656826
[TBL] [Abstract][Full Text] [Related]
11. Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma.
Tsibouris P; Hendrickse MT; Isaacs PE
Aliment Pharmacol Ther; 2004 Sep; 20(6):645-55. PubMed ID: 15352913
[TBL] [Abstract][Full Text] [Related]
12. 24-h pH monitoring is necessary to assess acid reflux suppression in patients with Barrett's oesophagus undergoing treatment with proton pump inhibitors.
Ortiz A; MartÃnez de Haro LF; Parrilla P; Molina J; Bermejo J; Munitiz V
Br J Surg; 1999 Nov; 86(11):1472-4. PubMed ID: 10583299
[TBL] [Abstract][Full Text] [Related]
13. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a histopathological and functional study.
Beales IL; Ogunwobi O; Cameron E; El-Amin K; Mutungi G; Wilkinson M
BMC Cancer; 2007 Jun; 7():97. PubMed ID: 17559672
[TBL] [Abstract][Full Text] [Related]
14. Chemoprevention in Barrett's oesophagus.
Gordon V; Jankowski J
Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):569-79. PubMed ID: 22122772
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer.
Wolfsen HC; Hemminger LL; Wallace MB; Devault KR
Aliment Pharmacol Ther; 2004 Nov; 20(10):1125-31. PubMed ID: 15569115
[TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma.
Weston AP; Badr AS; Topalovski M; Cherian R; Dixon A; Hassanein RS
Am J Gastroenterol; 2000 Feb; 95(2):387-94. PubMed ID: 10685740
[TBL] [Abstract][Full Text] [Related]
17. [The clinical strategy for the Barrett's esophagus].
Kitabatake S; Niwa Y; Goto H
Nihon Rinsho; 2005 Aug; 63(8):1434-7. PubMed ID: 16101235
[TBL] [Abstract][Full Text] [Related]
18. Colorectal neoplasia in veterans is associated with Barrett's esophagus but not with proton-pump inhibitor or aspirin/NSAID use.
Siersema PD; Yu S; Sahbaie P; Steyerberg EW; Simpson PW; Kuipers EJ; Triadafilopoulos G
Gastrointest Endosc; 2006 Apr; 63(4):581-6. PubMed ID: 16564855
[TBL] [Abstract][Full Text] [Related]
19. [Endoscopic treatment of Barrett's oesophagus].
Boyer J
Ann Chir; 2006 Jan; 131(1):7-11. PubMed ID: 16376846
[TBL] [Abstract][Full Text] [Related]
20. Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma?
Quera R; O'Sullivan K; Quigley EM
Endoscopy; 2006 Feb; 38(2):162-9. PubMed ID: 16479424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]